四環醫藥(00460.HK)擬分拆軒竹生物於內地科創板上市申請獲上交所受理
四環醫藥(00460.HK)公佈,有關建議分拆其非全資附屬軒竹生物於上交所科創板獨立上市,於昨日(26日)收到上交所就上市申請作出的受理通知。
目前,公司間接持有軒竹生物已發行股份總數約62.3892%。擬A股上市完成後,預期軒竹生物仍將爲公司之附屬。擬A股上市以上交所之審覈及中證監之註冊爲條件。目前發售的條款(包括最終發售的規模及價格範圍)及擬A股上市之時間表尚未確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.